Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-04

FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Original Application (Viona Pharmaceuticals Inc)

View source ↗

Summary

The FDA approves an original application for a generic fixed-dose combination of bisoprolol fumarate and hydrochlorothiazide for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bisoprolol Fumarate and Hydrochlorothiazide (bisoprolol fumarate and hydrochlorothiazide)

Snippet

ORIG AP for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)